Recent Progress in Polymer Therapeutics as Nanomedicines - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 113

33. Chytil, P., et al., N -(2-Hydroxypropyl)methacrylamide-based polymer
conjugates with pH-controlled activation of doxorubicin for cell-
specific or passive tumour targeting. Synthesis by RAFT polymerisation
and physicochemical characterisation . Eur J Pharm Sci , 2010. 41 (3-4):
p. 473-482.
34. Ulbrich, K., et al., Polymeric conjugates of drugs and antibodies for site-
specific drug delivery. Macromol Symp, 1996. 103 : p. 177-192.
35. Putnam, D. and J. Kopecek, Polymer conjugates with anticancer activity.
Biopolymers II, 1995. 122 : p. 55-123.
36. Ulbrich, K. and V. Subr, Polymeric anticancer drugs with pH-controlled
activation. Adv Drug Deliv Rev, 2004. 56 (7): p. 1023-1050.
37. Kratz, F., U. Beyer, and M.T. Schutte, Drug-polymer conjugates containing
acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst, 1999. 16 (3): p.
245-288.
38. Rodrigues, P.C.A., et al., Correlation of the acid-sensitivity of polyethylene
glycol daunorubicin conjugates with their in vitro antiproliferative
activity . Bioorg Med Chem, 2006. 14 (12): p. 4110-4117.
39. Meng, F.H., W.E. Hennink, and Z. Zhong, Reduction-sensitive polymers
and bioconjugates for biomedical applications. Biomaterials, 2009.
30 (12): p. 2180-2198.
40. Kopeček, J., et al., Synthetic polymeric drugs , U.S. Patent, Editor. 1991.
41. Miller, K., et al., Targeting bone metastases with a bispecific anticancer
and antiangiogenic polymer-alendronate-taxane conjugate. Angew
Chem Int Ed Engl, 2009. 48 (16): p. 2949-2954.
42. Dubowchik, G.M., et al., Cathepsin B-labile dipeptide linkers for
lysosomal release of doxorubicin from internalizing immunoconjugates:
model studies of enzymatic drug release and antigen-specific in vitro
anticancer activity. Bioconjug Chem, 2002. 13 (4): p. 855-869.
43. Liu, C., et al., Overexpression of legumain in tumors is significant for
invasion/metastasis and a candidate enzymatic target for prodrug
therapy. Cancer Res, 2003. 63 (11): p. 2957-2964.
44. Stern, L., et al., A novel antitumor prodrug platform designed to be
cleaved by the endoprotease legumain. Bioconjug Chem, 2009. 20 (3):
p. 500-510.
45. Kratz, F., et al., Development and in vitro efficacy of novel MMP2 and
MMP9 specific doxorubicin albumin conjugates. Bioorg Med Chem Lett,
2001. 11 (15): p. 2001-2006.
46. Kratz, F., et al., Prodrug strategies in anticancer chemotherapy.
ChemMedChem, 2008. 3 (1): p. 20-53.